twoXAR: SK Biopharma signs contract with US new drug developer
SK Biopharmaceuticals, a drug development unit of South Korea’s telecom-to-energy conglomerate SK Group, announced on April 18 that it has signed a contract with US-based biotech company twoXAR to co-develop a new drug for treating non-small cell lung cancer.
Read full article »
twoXAR is an AI-based platform that offers drug discovery, biomedical informatics, predictive analytics and preclinical validation solutions.
Read more